Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (‘clinical super response’): Week 28 results from the ongoing phase IIIb randomized, double‐blind, parallel‐group, GUIDE study: An analysis with considerations for future studies

Data sharing is not applicable to this article as no new data were created or analyzed in this study.